New anticancer drug Genotoxicity Clinical trial Synthesis pathways Side Effects
ChemicalBook > CAS DataBase List > Neratinib

Neratinib

New anticancer drug Genotoxicity Clinical trial Synthesis pathways Side Effects
Product Name
Neratinib
CAS No.
698387-09-6
Chemical Name
Neratinib
Synonyms
(2e)-n-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide;CS-26;PB-272;101028;neratinib;nevatinib;PF-0528767;WAY-179272;Unii-jjh94R3pwb;Neratinib Base.
CBNumber
CB2855051
Molecular Formula
C30H29ClN6O3
Formula Weight
557.04
MOL File
698387-09-6.mol
More
Less

Neratinib Property

Melting point:
185-187°C
Boiling point:
757.0±60.0 °C(Predicted)
Density 
1.33
storage temp. 
Refrigerator
solubility 
Chloroform (Slightly), DMSO (Slightly, Heated, Sonicated), Methanol (Slightly, Heated)
form 
Off-white solid.
pka
12.37±0.43(Predicted)
color 
Pale Yellow to Yellow
More
Less

Safety

HS Code 
29334900
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H290May be corrosive to metals

H314Causes severe skin burns and eye damage

Precautionary statements

P234Keep only in original container.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P330+P331IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.

P303+P361+P353IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.

P363Wash contaminated clothing before reuse.

P390Absorb spillage to prevent material damage.

P405Store locked up.

P406Store in corrosive resistant/… container with a resistant inner liner.

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
18404
Product name
Neratinib
Purity
≥98%
Packaging
50 mg
Price
$97
Updated
2024/03/01
Cayman Chemical
Product number
18404
Product name
Neratinib
Purity
≥98%
Packaging
100 mg
Price
$150
Updated
2024/03/01
Cayman Chemical
Product number
18404
Product name
Neratinib
Purity
≥98%
Packaging
5mg
Price
$43
Updated
2023/01/06
Cayman Chemical
Product number
18404
Product name
Neratinib
Purity
≥98%
Packaging
1mg
Price
$35
Updated
2021/12/16
Cayman Chemical
Product number
18404
Product name
Neratinib
Purity
≥98%
Packaging
10mg
Price
$43
Updated
2024/03/01
More
Less

Neratinib Chemical Properties,Usage,Production

New anticancer drug

Neratinib developed by US Wyeth company is an irreversible epidermal growth factor receptor(EGFR) inhibitor. It is a multiple target point of small molecule tyrosine kinase inhibitors to HER 2 and HER1 after Lapatinib, and is an irreversible ErbB receptor tyrosine kinase inhibitor. Neratinib could selectively inhibit HER-1 and HER-2 of EGFR family(IC50 was 92 nmol/L and 59 nmol/L, respectively). Clinical research showed that Neratinib exerted significant therapeutic effect on non-small cell lung cancer, colon cancer, and breast cancer.
The phaseⅡclinical trial indicated that Neratinib showed good efficacy and tolerance to HER-2 positive patients with advanced breast cancer who had been received or not Trastuzumab treatment.
The phase Ⅲ breast cancer clinical trial was complete in September 2014. The data indicated that the efficacy of Neratinib was better than Roche's Herceptin in treatment of HER-2 positive early breast cancer.
The above information is edited by the Chemicalbook of Liu Yujie.

Genotoxicity

Neratinib and its metabolites were not genotoxic. Administration of neratinib to pregnant rabbits during organogenesis resulted in abortions, embryo-fetal death, and fetal abnormalities at maternal exposures (AUC) approximately 0.2 times exposures in patients at the recommended dose. Oral administration of neratinib to pregnant rats from gestation day 7 until lactation day 20 resulted in effects on long-term memory in male offspring at maternal doses less than the maximum recommended clinical dose on a mg/m2 basis. Neratinib was not carcinogenic in a 26-week carcinogenicity study in rasH2 transgenic mice.

Clinical trial

Neratinib was tested in a phase II trial as monotherapy in 2 cohorts of patients with advanced HER2-positive breast cancer those with and those without previous trastuzumab treatment. Sixteen-week progression-free survival (PFS) rates were 59% for patients with previous trastuzumab treatment and 78% for patients with no previous trastuzumab treatment with a median PFS of 22.3 and 39.6 weeks, respectively. Objective response rates were 24% among patients with previous trastuzumab treatment and 56% in the trastuzumab-naive cohort.[4]

Synthesis pathways

3-chloro-4-(pyridin-2-yl-methoxy)-aniline (2) and N-(4-chloro-3-cyano-7-ethoxy-quinolin-6-yl)-acetamide (3) are used as raw material to prepare N-[4-[3-chloro-4-(pyridin-2-yl-methoxy) anilino]-3-cyano-7-ethoxy-quinolin-6-yl] acetamide (4) by nucleophilic substitution. Deprotection of 4 was under the effect of hydrochloric acid, then was precipitated the free base in methanol solution of potassium carbonate to prepare 6-amino-3-cyano-4-[3-chloro-4-(pyridin-2-yl-methoxy) anilino]-7-ethoxy-quinoline (5). Neratinib(1) was obtained by condensation of 5 and acyl chloride which was prepared by trans-4-dimethylamino-crotonic acid hydrochloride (6).

Figure 1 Synthesis pathways of Neratinib

Side Effects

Diarrhea, nausea, vomiting, and fatigue.

Description

The receptor tyrosine kinase HER2 (ErbB2) is a key component of epidermal growth factor receptor complexes that are known to have central roles in cell proliferation and cancer. Neratinib is an orally active, irreversible inhibitor of the HER2 kinase (IC50 = 59 nM). It also potently inhibits several mutants of HER2 and shows 10-fold or greater selectivity over a wide variety of other kinases. As an irreversible inhibitor, neratinib may circumvent acquired resistance developed against reversible inhibitors, including gefitinib . Neratinib has been evaluated in clinical trials against cancers characterized by HER2 overexpression or HER2 activating mutations.

Uses

Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM, respectively.

Uses

An oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Antitumor agent.

Definition

ChEBI: A quinoline compound having a cyano group at the 3-position, a 3-chloro-4-(2-pyridylmethoxy)anilino group at the 4-position, a 4-dimethylamino-trans-but-2-enamido group at the 6-position, and an ethoxy group at the 7-position.

target

HER2

storage

Store at -20°C

Neratinib Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Neratinib Suppliers

Hubei Haiyue Biotechnology Co., Ltd
Tel
15926453367
Email
haiyue1682022@163.com
Country
China
ProdList
251
Advantage
58
Shanghai jing Hao pharmaceutical technology co., LTD
Tel
021-68900963 15618693615
Fax
021-68900963
Email
sales@jinghaopharma.com
Country
China
ProdList
310
Advantage
58
Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2923
Advantage
55
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
94838
Advantage
76
Chembest Research Laboratories Limited
Tel
021-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6011
Advantage
61
JinYan Chemicals(ShangHai) Co.,Ltd.
Tel
13817811078
Fax
86-021-50426522,50426273
Email
sales@jingyan-chemical.com
Country
China
ProdList
9984
Advantage
60
Jia Xing Isenchem Co.,Ltd
Tel
0573-85285100 18627885956
Fax
0573-85285100
Email
isenchem@163.com
Country
China
ProdList
9551
Advantage
66
Shanghai Boc Chemical Co.,Ltd
Tel
021-34975603-808 18721111801
Fax
+86-21-34975602-805
Email
sales@bocpharma.com
Country
China
ProdList
994
Advantage
64
Nanjing Chemlin Chemical Co., Ltd
Tel
025-83697070
Fax
+86-25-83453306
Email
info@chemlin.com.cn
Country
China
ProdList
17988
Advantage
64
Shanghai Hanhong Scientific Co.,Ltd.
Tel
021-54306202 13764082696;
Email
info@hanhongsci.com
Country
China
ProdList
42982
Advantage
64
More
Less

View Lastest Price from Neratinib manufacturers

shandong perfect biotechnology co.ltd
Product
Neratinib (HKI-272) 698387-09-6
Price
US $0.00/g
Min. Order
1g
Purity
98% HPLC
Supply Ability
1KG
Release date
2023-08-02
Hebei Duling International Trade Co. LTD
Product
Neratinib 698387-09-6
Price
US $1.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
5000 Ton
Release date
2022-10-19
Nanjing Fred Technology Co., Ltd
Product
Neratinib 698387-09-6
Price
US $0.00-0.00/kg
Min. Order
1kg
Purity
99%,single impurity<0.1
Supply Ability
1 ton
Release date
2023-12-22

698387-09-6, NeratinibRelated Search:


  • (2e)-n-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
  • Neratinib(HKI-272)
  • (2E)-N-[4-[[3-chloro-4-(2-pyridinylMethoxy)phenyl]aMino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(diMethylaMino)-2-butenaMide
  • neratinib
  • (E)-N-[4-[3-Chloro-4-[(2-pyridinyl)methoxy]anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
  • N-(4-(3-Chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide
  • Unii-jjh94R3pwb
  • HKI-272; HKI272; HKI 272
  • CS-26
  • (2e)-n-(4-((3-chloro-4-((pyridin-2-yl)Methoxy)phenyl)aMino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(diMethylaMino)but-2-enaMide neratinib
  • HKI-272 Neratinib
  • Neratinib HKI-272 (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
  • Neratinib (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
  • (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-emide
  • PB272(neratinib)
  • 2-ButenaMide,N-[4-[[3-chloro-4-(2-pyridinylMethoxy)phenyl]aMino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(diMethylaMino)-,(2E)-
  • Neratinib, >=99%
  • PB-272
  • PF-0528767
  • WAY-179272
  • (E)-N-(4-(3-Chloro-4-(pyridin-2-yLmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimet
  • Neratinib API and intermediates
  • Neratinib, 99%, a highly selective HER2 and EGFR inhibitor
  • nevatinib
  • 101028
  • Lenatinib Impurity E
  • Neratinib USP/EP/BP
  • (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
  • Neratinib Base.
  • 698387-09-6
  • 688387-09-6
  • C30H29ClN6O3
  • C30H31ClN6O2
  • Inhibitors
  • Anti-cancer & immunity
  • Antineoplastic
  • API